Ilias Biologics develops exosome-based therapeutics using its EXPLOR® platform, a novel protein-loading method that enables free-form loading of large therapeutic proteins into exosome lumens. The company’s lead candidate, ILB-202, produced promising preclinical data published in Science Advances, and Ilias secured a key exosome engineering patent from the USPTO in July. The Series B proceeds will support continued development of the EXPLOR platform and advancement of its exosome therapeutics pipeline across inflammatory diseases and oncology. Ilias plans to submit an IND to the U.S. FDA and initiate a first-in-human clinical trial by the second half of 2021 targeting an undisclosed acute inflammatory disease, and is in active discussions with multiple pharmaceutical companies for potential collaborations. Financially, the company has raised a total of $40.2M since its foundation in November 2015. Management is led by CEO Dr. Chulhee Choi and is planning an IPO on KOSDAQ in Q1 2022, with underwriter contracts being finalized.

Total raised

$21M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2020